文献速递免疫规划

一项评估新型重组戊型肝炎疫苗安全性与耐受性的1期随机开放标签临床研究

A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine.
PubMed 文献 · Vaccine · 2017-08-10

该1期随机开放标签平行对照试验纳入中国江苏省120名16-65岁合格参与者,实验组分别接种20μg、30μg和40μg戊型肝炎病毒p179疫苗,以30μg戊型肝炎疫苗p239 Hecolin为对照,按0、1、6月间隔接种。实验组征集性局部不良反应发生率显著低于对照组(P=0.027),征集性总不良反应和全身不良反应发生率组间无显著差异(P>0.05),未发生疫苗相关严重不良事件。三种剂量p179疫苗被认为安全且耐受性良好,30μg剂量被选用于进一步有效性研究。

要点

  • 实验组征集性局部不良反应发生率显著低于对照组(P=0.027)。
  • 征集性总不良反应和全身不良反应发生率实验组与对照组无显著差异(P>0.05)。
  • 未发生疫苗相关严重不良事件,30μg剂量被选用于进一步有效性研究。

核心结论

  • 三种不同剂量的戊型肝炎病毒p179疫苗被认为安全且耐受性良好。
  • 未发现疫苗相关严重不良事件,30μg剂量被选用于进一步有效性研究。

研究设计与样本

  • 1期随机开放标签平行对照临床试验纳入中国江苏省120名16-65岁合格参与者。
  • 实验组随机接种20μg、30μg和40μg戊型肝炎病毒p179疫苗,以30μg戊型肝炎疫苗p239 Hecolin为对照,按0、1、6月间隔接种。
  • 每次接种后7天内观察征集性局部和全身不良反应,接种后6个月内观察任何严重不良事件。
  • 每次注射前3天和注射后采集血样,测定血常规和血清生化指标。

主要发现

  • 实验组征集性局部不良反应发生率显著低于对照组(P=0.027)。
  • 实验组与对照组征集性总不良反应和全身不良反应发生率差异无显著差异(P>0.05)。
  • 按不同等级和症状分析不良反应时观察到相似模式。
  • 不同疫苗接种前后血液生化指标和血常规检查变化均为轻度(1级)或中度(2级),实验组与对照组差异无统计学显著差异。
  • 研究期间所有受试者均未发生疫苗相关严重不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to evaluate the safety and tolerability for variable dosages of a novel hepatitis E vaccine p179. METHODS: The randomized open-label parallel control phase 1 clinical trial enrolled 120 eligible participants aged 16-65years in Jiangsu Province, China. The experimental groups were randomized to receive different dosages of 20μg, 30μg, and 40μg Hepatitis E Virus (HEV) p179 vaccines, with the 30μgHEV vaccine p239 Hecolin as control, and vaccinated at 0, 1 and 6month intervals. Participants were observed for solicited local and systemic adverse reactions (ARs) occurring within 7days after each vaccination, and any serious adverse events (SAEs) occurring within 6months post-vaccination. Blood samples were collected from participants 3days before and after each injection, to determine the blood routine and serum biochemical indexes. RESULTS: The solicited local ARs incidence in experimental groups were significantly lower than that of the control group (P=0.027). The difference between solicited total and systemic ARs incidence of experimental groups and the control group were not significant (P>0.05). Similar patterns were observed when the analyses were performed on the group having ARs of varying grades and symptoms. All changes in blood biochemical indexes and routine blood tests before and after different vaccinations were mild (grade 1) or moderate (grade 2), and the difference in experimental groups and the control group were not statistically significant. No vaccine related SAEs occurred in any of the subjects during the study. CONCLUSION: Three different dosages of HEV p179 vaccine were deemed safe and well tolerated. No vaccine-associated SAEs were identified, and the 30μg dosage formulation was selected for further investigation for efficacy. Clinical trials registration number: 2012L01657.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cao YF, Tao H, Hu YM, et al. A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine. Vaccine. 2017. PMID: 28803715. doi:10.1016/j.vaccine.2017.05.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。